MEDVi Review 2026: Oral and Injectable GLP-1 Options

MEDVi does not publish a price. On September 20, 2026 the price fields on its GLP-1 page rendered as unresolved template code rather than numbers — “GLP-1 Injections: Starting at ${seminject_sale_price}”, “GLP-1 Tablets: Starting at ${semtab_sale_price}” — so no monthly figure is readable before you enter the intake funnel.

The only MEDVi figures in public are in its own 2025 announcements, and two of them disagree. They are listed below as dated company statements, not current prices.

MEDVi’s GLP-1 page lists five choices, a wider menu than most programs offer: “GLP-1 Injections (weekly)”, “GLP-1 Tablets (daily, dissolvable)”, “Wegovy® Pill”, “Wegovy® Injection” and “Zepbound® Injection”.

The first two are compounded preparations of semaglutide and tirzepatide. Compounded drugs are not FDA-approved: the FDA “does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.” MEDVi states this itself in its homepage footer — “Compound medications are dispensed by state-licensed pharmacies but are not FDA approved.” The last three are FDA-approved brand-name medicines, so if a clinician rules out a compounded preparation you need not start again elsewhere.

The oral tablets

Oral compounded semaglutide and tirzepatide are the unusual part of this menu, and oral tirzepatide is rare. MEDVi announced them on October 14, 2025, markets them as “needle-free”, and states in that announcement that the tablets “are not approved by the U.S. Food and Drug Administration.”

MEDVi publishes no strength, salt form, excipient list, bioavailability figure or clinical data for them. The FDA notes that salt forms “including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs.” Ask the clinician for the strength and exact ingredient before you start.

MEDVi, LLC is based at 131 Continental Dr, Ste 305, Newark, DE 19713. It does not deliver the care: treatment comes from “CareGLP Affiliated P.C.s” and OpenLoop Health, and MEDVi states it “is not acting as a pharmacy.”

The consent puts prescribing with that network: “OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients.” OpenLoop describes a “50-state clinician network” of US-licensed providers.

MEDVi also names its pharmacies on the homepage, with addresses: Triad Rx in Daphne, Alabama; RedRock Pharmacy in St. George, Utah; and Beaker Pharmacy & Compounding in McKinney, Texas. Many GLP-1 brands name none, so this is a real advantage. Missing is the mapping: no page says which pharmacy fills which product, or whether each is a 503A pharmacy or a 503B outsourcing facility. Worth asking, since the FDA says outsourcing facilities “are subject to current good manufacturing practice (CGMP) requirements” while pharmacy compounding is not.

Two statements sit side by side. MEDVi says compounded GLP-1s “are produced in FDA-regulated facilities” while “not FDA-approved”; the FDA’s June 2026 telehealth guidance lists “claiming a compounded drug is sourced from an FDA-approved… pharmacy” among claims it tells companies not to make.

Which states

MEDVi’s answers do not line up, so here are all three. The terms on both domains say: “The Services are currently available to individuals located in certain states. To see the list of current states, please contact customer service at help@medvi.org.” The July 30, 2025 announcement claims “Service availability in all 50 U.S. states.” The October 14, 2025 one says MEDVi operates in “select states”. No list is published, so customer service is the only reliable route.

Age and the visit

You must be “at least 18 years of age or older”. The consent defines telehealth generally as care using an “audio-video interface such as videoconferencing,” but no MEDVi page says a live video appointment is required or included. The published flow is a questionnaire followed by asynchronous clinician review, with MEDVi’s men’s health program describing a doctor review within 24 hours. If a live call matters, confirm it is available first.

Shipping, support and payment

The page advertises “Medication shipped to door” with “Fast, free shipping”, “Unlimited 24/7 support with specialists”, a metabolic report and “1:1 guidance and coaching”. Free dietitian visits carry the asterisk “subject to insurance and copays eligibility to be determined at time of visit.” HSA and FSA payment is accepted; the medication is cash-pay.

Settle this before you pay. MEDVi has two refund policies live at once, on domains it controls, and they grant different rights. The home.medvi.org version is linked from the homepage; the medvi.org version is the older path, still live and still linked from MEDVi’s men’s health program.

The documents differ: the homepage version grants a 72-hour full-refund window and refunds unshipped months on multi-month plans; the legacy version recognises only medical disqualification. Both were live on September 20, 2026, and MEDVi does not say which governs a new order. Ask in writing and keep the reply.

Three points apply either way. Consult fees are non-refundable: “medical consult fees are not subject to or eligible for a refund.” Medication is final sale: “we cannot accept returns of prescription products… and all sales are final.” Both policies note federal law generally bars returning dispensed medication.

To cancel: “Contact customer service at hello@medvi.org or use the patient portal chat feature.” Disputes “WILL BE RESOLVED EXCLUSIVELY BY BINDING ARBITRATION”, and “YOU AND WE ARE EACH WAIVING THE RIGHT TO PARTICIPATE IN A CLASS ACTION”. Note your billing date and cancel by email more than 72 hours ahead.

Figures read September 20, 2026.

The two BBB counts come from different parts of the same profile and do not agree — 723 with 126 unanswered in the rating box, 709 with 122 on the complaints page — so we report both.

Trustpilot’s own number is not the only one in circulation. The profile displayed 4.3 out of 5 on September 20, 2026; a Trustpilot search-result title read the same day said 4.4 out of 5; and MEDVi’s own Quad page advertises “Excellent 4.5 out of 5”. The three differ, and we report all three rather than picking one.

One regulatory matter: on February 20, 2026 the FDA issued Warning Letter #721455 to MEDVi, LLC concerning its marketing of compounded semaglutide and tirzepatide, citing website claims that the products contain the same active ingredient as four named brand-name drugs and MEDVi-branded labelling that the letter says suggested MEDVi was the compounder, under sections 502(a), 502(bb), 301(a) and 301(c) of the Federal Food, Drug, and Cosmetic Act; we found no close-out letter as of September 20, 2026.

Four emailed questions do most of the work: the first-month and refill price for your product, and the medication cost on top of any membership; whether your state is served; which refund policy governs your order; and which pharmacy will fill it.

See how we review for the six criteria behind these findings. MEDVi’s men’s health program is covered separately in our Quad by MEDVi review — same company and terms, different product. For GLP-1 programs that do publish prices, see Trim Rx and Trimi, or the full GLP-1 clinic comparison. Our GLP-1 telehealth pricing guide explains these membership-plus-medication structures.